PMID- 23312076
OWN - NLM
STAT- MEDLINE
DCOM- 20130925
LR  - 20131121
IS  - 1475-2662 (Electronic)
IS  - 0007-1145 (Linking)
VI  - 110
IP  - 3
DP  - 2013 Aug 28
TI  - Adding MUFA to a dietary portfolio of cholesterol-lowering foods reduces apoAI 
      fractional catabolic rate in subjects with dyslipidaemia.
PG  - 426-36
LID - 10.1017/S000711451200534X [doi]
AB  - The present randomised parallel study assessed the impact of adding MUFA to a 
      dietary portfolio of cholesterol-lowering foods on the intravascular kinetics of 
      apoAI- and apoB-containing lipoproteins in subjects with dyslipidaemia. A sample 
      of sixteen men and postmenopausal women consumed a run-in stabilisation diet for 
      4 weeks. Subjects were then randomly assigned to an experimental dietary 
      portfolio either high or low in MUFA for another 4 weeks. MUFA substituted 13.0% 
      of total energy from carbohydrate (CHO) in the high-MUFA dietary portfolio. 
      Lipoprotein kinetics were assessed after the run-in and portfolio diets using a 
      primed, constant infusion of [2H3]leucine and multicompartmental modelling. The 
      high-MUFA dietary portfolio resulted in higher apoAI pool size (PS) compared with 
      the low-MUFA dietary portfolio (15.9% between-diet difference, P(1/4)0.03). This 
      difference appeared to be mainly attributable to a reduction in apoAI fractional 
      catabolic rate (FCR) after the high-MUFA diet (25.6%, P(1/4)0.02 v. pre-diet values), 
      with no significant change in production rate. The high-MUFA dietary portfolio 
      tended to reduce LDL apoB100 PS compared with the low-MUFA dietary portfolio 
      (228.5% between-diet that adding MUFA to a dietary portfolio of 
      cholesterol-lowering foods provides the added advantage of raising HDL primarily 
      through a reduction in HDL clearance rate. Replacing CHO with MUFA in a dietary 
      portfolio may also lead to reductions in LDL apoB100 concentrations primarily by 
      increasing LDL clearance rate, thus potentiating further the well-known 
      cholesterol-lowering effect of this diet.
FAU - Labonte, Marie-Eve
AU  - Labonte ME
AD  - Institute of Nutraceuticals and Functional Foods, Laval University, 2440, 
      Boulevard Hochelaga, Quebec, QC, Canada G1V 0A6.
FAU - Jenkins, David J A
AU  - Jenkins DJ
FAU - Lewis, Gary F
AU  - Lewis GF
FAU - Chiavaroli, Laura
AU  - Chiavaroli L
FAU - Wong, Julia M W
AU  - Wong JM
FAU - Kendall, Cyril W C
AU  - Kendall CW
FAU - Hogue, Jean-Charles
AU  - Hogue JC
FAU - Couture, Patrick
AU  - Couture P
FAU - Lamarche, Benoit
AU  - Lamarche B
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130114
PL  - England
TA  - Br J Nutr
JT  - The British journal of nutrition
JID - 0372547
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Apolipoprotein A-I)
RN  - 0 (Apolipoprotein B-100)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Dietary Carbohydrates)
RN  - 0 (Dietary Fats)
RN  - 0 (Fatty Acids, Monounsaturated)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Adult
MH  - Anticholesteremic Agents/*pharmacology/therapeutic use
MH  - Apolipoprotein A-I/*blood
MH  - Apolipoprotein B-100/*blood
MH  - Cholesterol/*blood
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Dietary Carbohydrates/pharmacology
MH  - Dietary Fats/blood/*pharmacology
MH  - Dyslipidemias/blood/*diet therapy
MH  - Fatty Acids, Monounsaturated/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Postmenopause
EDAT- 2013/01/15 06:00
MHDA- 2013/09/26 06:00
CRDT- 2013/01/15 06:00
PHST- 2013/01/15 06:00 [entrez]
PHST- 2013/01/15 06:00 [pubmed]
PHST- 2013/09/26 06:00 [medline]
AID - S000711451200534X [pii]
AID - 10.1017/S000711451200534X [doi]
PST - ppublish
SO  - Br J Nutr. 2013 Aug 28;110(3):426-36. doi: 10.1017/S000711451200534X. Epub 2013 
      Jan 14.